Since then, many trials have demonstrated the efficacy of Gilteritinib, a third generation FLT3 inhibitor recently approved in refractory or relapsed FLT3 mutated AML [89,90,91,92,93]. The gene discussed is FLT3; the disease is acute myeloid leukemia.